the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients (HAS)
Retrospective Study That Evaluate the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Patients With Primary Sjogren Syndrome
sjogren syndrome is an autoimmune disease that mainly affects the Salivary glands and Lacrimal gland In addition to the effects of this disease is characterized by overall systemic Muskals injury, pulmonary disease, peripheral neuropathy and vasculitis. In addition recent studies have shown that patients are at increased risk of the disease up to 2 cardiac events and stroke events Hydroxychloroquine is an RHEUMATIC DISEASE PROCESS SUPPRESSANTS-ANTIMALARIALS used to treat anti-inflammatory rheumatic diseases in many first-line treatment is sjogren syndrome.
A recent study of the treatment in Hydroxychloroquine effect on lipid profile sjogren syndrome patients showed a reduction in total cholesterol levels and increase in HDL. Further studies of the impact made Hydroxychloroquine systemic lupus patients erythematosus (SLE) showed in Atherosclerosis and morbidity and mortality reduction in cardiovascular. Studies of patients with rheumatoid arthritis (RA) demonstrated reduced risk of developing diabetes and improved lipid profile Research Goals valuate The effect of HCQ treatment in cardiovascular patients with primary sjogren syndrome
연구 개요
상세 설명
Research Goals Valuate The effect of HCQ treatment in cardiovascular patients with primary sjogren syndrome Research Methods The study will included patients that diagnosed with sjogren syndrome and was treated in Meir Medical center during the years 2003-2014 During the study will collect information on confounding factors , Risk factors include cardiovascular acceptable such as diabetes, dyslipidemia, high blood pressure and the like, central nervous system involvement and steroid use
Study outcome will be one of the follow:
- Thrombosis of peripheral veins
- Arterial cardiovascular events
- Cardiac events (myocardial infarction
- Stroke (stroke and TIA)
4. Venous thrombosis events 5. Pulmonary embolism In the study will be 500 patients
Inclusion criteria:
- 18 years old
- Both sexes
- Patients that diagnosis in sjogren in treated in Meir Medical center in the years 2003-2014 And treated in Hydroxychloroquine at least a month.
Exclusion criteria:
- Minors and special populations
- Patients that treated in Hydroxychloroquine at less than a month.
- Patient that participate in clinical trial and treat with investigational product
연구 유형
등록 (예상)
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- 18 years old
- Both sexes
- Patients that diagnosis in sjogren in treated in Meir Medical center in the years 2003-2014 And treated in Hydroxychloroquine at least a month.
Exclusion Criteria:
- Minors and special populations
- Patients that treated in Hydroxychloroquine at less than a month.
- Patient that participate in clinical trial and treat with investigational product
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Arterial cardiovascular events
기간: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Cardiac events (myocardial infarction
기간: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Thrombosis of peripheral veins
기간: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Stroke (stroke and TIA)
기간: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Venous thrombosis events
기간: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Pulmonary embolism
기간: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .